Cohort Study Investigating the Association Between Antichlamydial Antibody Positivity and ART Outcomes in Women With TFI

NCT04139629 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 292

Last updated 2021-08-24

No results posted yet for this study

Summary

In a prospective cohort study investigators will examine characteristics and clinical outcomes of treatment with ART in women with tubal factor infertility (TFI) with regard to seropositivity to antichlamydial antibodies.

Conditions

  • Antichlamydial Antibodies
  • Chlamydia Trachomatis Infection
  • Infertility
  • Tubal Factor Infertility

Interventions

DIAGNOSTIC_TEST

antichlamydial antibody test

At the first day of stimulation blood analyses for IgG, IgA and IgM (ELISA) to major chlamydial antigens (anti-C.trachomatis), major outer membrane protein (MOMP) and plasmid-encoded protein (pgp3) will be performed for patients found eligible for the study.

DRUG

treatment of infertility with ART

COS in gonadotropin-releasing hormone (GnRH) antagonist protocol with IVF/ICSI, fresh ET and, if no pregnancy occurred, frozen/thawed ET (for all embryos resulting from this COS) will be performed.

Sponsors & Collaborators

  • D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

    lead OTHER

Principal Investigators

  • Alexandr Gzgzyan, Prof, PhD · D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
41 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-25
Primary Completion
2020-01-30
Completion
2021-10-30

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04139629 on ClinicalTrials.gov